Rik J. Scheper
Impact in
- Oncology top 0.02%
- Drug Transport and Resistance Mechanisms
- CAR-T cell therapy research
- Immunology top 0.1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
Papers in
- Immunology 184
- Immunotherapy and Immune Responses 114
- T-cell and B-cell Immunology 85
- Immune Cell Function and Interaction 75
- Oncology 170
- Drug Transport and Resistance Mechanisms 107
- CAR-T cell therapy research 32
- Co-authors
- George L. Scheffer (83 shared papers)Tanja D. de Gruijl (96 shared papers)Herbert M. Pinedo (33 shared papers)Susan Gibbs (41 shared papers)Alfons J.M. van den Eertwegh (54 shared papers)Piet Borst (9 shared papers)B. Mary E. von Blomberg (57 shared papers)Marcel de Haas (6 shared papers)
- Journals
- International Journal of Cancer (21 papers)The Journal of Immunology (18 papers)Cancer Immunology Immunotherapy (18 papers)Blood (15 papers)Journal of Investigative Dermatology (13 papers)
- Partner nations
- NetherlandsUnited StatesGermany
In The Last Decade
Rik J. Scheper
390 papers receiving 26.3k citations
Rik J. Scheper's Hit Papers
Peers
Comparison fields: 5 of 157
- Oncology 13.2k
- Immunology 6.8k
- Dermatology 2.2k
- Pediatrics, Perinatology and Child Health 3.5k
- Immunology and Allergy 845
Countries citing papers authored by Rik J. Scheper
This map shows the geographic impact of Rik J. Scheper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rik J. Scheper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rik J. Scheper more than expected).
Fields of papers citing papers by Rik J. Scheper
This network shows the impact of papers produced by Rik J. Scheper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rik J. Scheper. The network helps show where Rik J. Scheper may publish in the future.
Co-authors
The 25 scholars most cited alongside Rik J. Scheper, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 396 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Hit paper breakdown → | 1997 | 745 |
| 2 | Congenital Jaundice in Rats with a Mutation in a Multidrug Resistance-Associated Protein Gene Hit paper breakdown → | 1996 | 696 |
| 3 | The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria Hit paper breakdown → | 2002 | 674 |
| 4 | The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Hit paper breakdown → | 1994 | 593 |
| 5 | Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Hit paper breakdown → | 1994 | 551 |
| 6 | MRP3, an organic anion transporter able to transport anti-cancer drugs Hit paper breakdown → | 1999 | 524 |
| 7 | The drug resistance-related protein LRP is the human major vault protein Hit paper breakdown → | 1995 | 512 |
| 8 | Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. Hit paper breakdown → | 1989 | 478 |
| 9 | Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. | 1993 | 433 |
| 10 | A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. | 2002 | 427 |
| 11 | 1997 | 416 | |
| 12 | Tissue distribution of the multidrug resistance protein. | 1996 | 406 |
| 13 | 2000 | 391 | |
| 14 | 1999 | 381 | |
| 15 | Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. | 1999 | 361 |
| 16 | 2008 | 358 | |
| 17 | 2004 | 322 | |
| 18 | 2012 | 291 | |
| 19 | 2000 | 282 | |
| 20 | 1988 | 247 |
About Rik J. Scheper
Rik J. Scheper is a scholar working on Immunology, Oncology, Molecular Biology, Dermatology and Surgery, having authored 396 papers that have together received 27.1k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (114 papers), Drug Transport and Resistance Mechanisms (107 papers), T-cell and B-cell Immunology (85 papers), Immune Cell Function and Interaction (75 papers), Contact Dermatitis and Allergies (40 papers), CAR-T cell therapy research (32 papers), Pharmacological Effects and Toxicity Studies (28 papers) and Monoclonal and Polyclonal Antibodies Research (23 papers). The work is most often cited by research in Oncology (13.2k citations), Immunology (6.8k citations), Dermatology (2.2k citations), Pediatrics, Perinatology and Child Health (3.5k citations) and Immunology and Allergy (845 citations). Rik J. Scheper has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include George L. Scheffer, Tanja D. de Gruijl, Herbert M. Pinedo, Susan Gibbs, Alfons J.M. van den Eertwegh, Piet Borst, B. Mary E. von Blomberg, Marcel de Haas, Frank Baas and Miguel Izquierdo. Their work appears in journals such as International Journal of Cancer, The Journal of Immunology, Cancer Immunology Immunotherapy, Blood and Journal of Investigative Dermatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.